2011 ADA Posters 1261-2041.indd - Diabetes

More documents

Recommendations

Info

1906-P Long-Term Weight Loss and Improvement in Glycemic Parameters with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/ TPM CR) ROBERT F. KUSHNER, W. TIMOTHY GARVEY, BARBARA TROUPIN, WESLEY W. DAY, Chicago, IL, Birmingham, AL, Mountain View, CA Obesity is an epidemic linked to chronic comorbidities, including type 2 diabetes mellitus (T2DM). Previously, weight loss associated with PHEN/ TPM CR demonstrated improvements in glycemic parameters through 56 weeks in the CONQUER study. SEQUEL, an extension of CONQUER, was conducted to evaluate long-term (108 weeks) effects of PHEN/TPM CR on weight loss and glycemic parameters related to T2DM. This double-blind extension maintained the original blinded treatment groups for an additional 52 weeks in subjects completing 56 weeks of CONQUER: placebo (PBO; n=227), PHEN 7.5 mg/TPM CR 46 mg (7.5/46; n=153), or PHEN 15 mg/TPM CR 92 mg (15/92; n=295). All subjects with T2DM were managed to the <strong>ADA</strong> standards of care. In the overall ITT-LOCF sample, least-squares (LS) mean percent weight loss was signifi cantly greater with both doses of PHEN/TPM CR compared with PBO (P
Integrated Physiology/ Obesity POSTERS The multiple adjusted odds ratio for those who had the lowest creatinine level (≤0.80mg/dL) was 1.785 (95% CI 1.145– 2.781) compared with those who had the highest creatinine level (1.01–1.20). In conclusion, lower serum creatinine was associated with an increased risk of glucose abnormality, but not other components of MS among obese Korean men. 1910-P Metabolic Syndrome Is Associated with Impaired Pulmonary Function in a Restrictive, but Not Obstructive, Pattern, in Japanese Men TAKEHIDE OGIHARA, NORIKO CHIKATSU, TAKESHI NAWA, RYOICHI NAMBA, YUSUKE YAMAMOTO, MICHIKO MURAOSA, SHINJI HIRAI, YUJI OKA, Hitachi, Japan Metabolic syndrome (MS) has been shown to be associated with impaired pulmonary function, especially chronic obstructive pulmonary disease (COPD). Systemic infl ammation is a possible mechanism underlying the association between these disorders. In this study, we investigated the effect of MS on pulmonary function by analyzing data from 9,573 men aged 22 to 89 years. Based on the diagnostic criteria for MS in Japan, current/former-smokers and those who never smoked were each divided into MS and non-MS groups. Then we examined the relationship between MS and measures of pulmonary function (including percentage predicted forced vital capacity; %FVC, percentage predicted forced expiratory volume in 1 s; %FEV 1 , and FEV 1 - to- FVC ratio). Next, we investigated the correlation between visceral fat area and each measure of pulmonary function. Lastly, we analyzed the infl uence of MS diagnostic criteria on each measure of pulmonary function using stepwise regression analysis. Non-smokers and smokers with MS showed signifi cantly lower %FVC and %FEV 1 than those without MS, respectively. However, FEV 1 - to-FVC ratio was signifi cantly higher in subjects with MS than in those without MS. Among smokers and non-smokers, visceral fat area showed weak negative correlations with %FVC and %FEV 1 . In the regression equation with %FVC as a dependent variable, waist circumference, blood pressure, lipids and fasting blood glucose were signifi cant negative explanatory variables. However, in that with FEV 1 - to-FVC ratio, lipids and fasting blood glucose were positive explanatory variables. Thus, indicators of impaired pulmonary function associated with MS are %FVC and %FEV 1 , suggesting that MS is associated with impaired pulmonary function in a restrictive, but not obstructive, pattern. As airfl ow limitation for the diagnosis of COPD is judged by FEV 1 - to-FVC ratio, there is a risk of missing early COPD among smokers with MS. Therefore, smokers with MS should be advised early of the need for smoking cessation. 1911-P Metabolically Healthy Obese Individuals Have Decreased Heart Failure Risk Compared to Normal-Weight People in a Six-Year Mediter ranean Study VASILLIS VOULGARIS, CHRISTINA VOULGARI, NICHOLAS TENTOLOURIS, PAUL POIRIER, Athens, Greece, Quebec, QC, Canada Heart failure (HF) is one of the leading causes of mortality and its prevalence continues to rise, despite the decline in cardiovascular death rates. Among the risk factors identifi ed as consistently associated with its development are Obesity and Metabolic Syndrome (MetS). “Metabolically Healthy Obese” (MHO) people, despite their body fat, display a favorable metabolic profi le characterized by high levels of insulin-sensitivity, and a benefi cial bloodpressure, glycemic, lipids, and infl ammation profi le. It remains controversial whether this healthier metabolic profi le is translated into a lower cardiovascular risk compared with normal-weight individuals with MetS. A total of 550 individuals without diabetes or baseline macrovascular complications were studied. Participants were classifi ed by presence (n=271) or absence (n=279) of MetS and by BMI (BMI;
Page 1 and 2:
Integrated Physiology/ Obesity POST
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24: Integrated Physiology/ Obesity POST
Page 73: Integrated Physiology/ Obesity POST
show all

2011 ADA Posters 1261-2041.indd - Diabetes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?